ResMed, the company best known for its sleep apnea devices, is taking a significant loss on its healthcare software business to refocus on its core operations. The firm announced it is selling its MatrixCare and HealthCare First software units to Frazier Healthcare Partners for $490 million—a price far below the $876 million it originally paid for the two businesses.
The move marks a strategic retreat from parts of ResMed's software expansion. The company had built up a healthcare software arm alongside its primary medical device business, but the residential care software division has underperformed recently. According to investment bank Jarden, the unit has delivered weaker growth and lower profit margins, which helps explain why ResMed is willing to accept a steep discount on its earlier investment.
What the Sale Means for ResMed's Strategy
ResMed's core business remains sleep apnea treatment—devices like CPAP machines and masks that help patients breathe during sleep. The company had diversified into healthcare software to complement its medical devices, but the sale signals a shift back toward its roots. By divesting MatrixCare and HealthCare First, ResMed can concentrate resources on its sleep and home care offerings, which are more closely tied to its main revenue stream.
The sale is part of a broader trend among companies reassessing their portfolios. Similar moves have been seen across industries, such as Synopsys phasing out fab software to focus on higher-margin AI design and Shell selling its South Africa downstream business to ADNOC. These decisions often involve taking a short-term financial hit to improve long-term focus.
Buyback Plan to Support Earnings Per Share
To offset the financial impact of the sale, ResMed plans to increase its share buyback program. A share buyback reduces the number of shares outstanding, which can boost earnings per share (EPS) even if total profits don't change. This is a common tactic companies use when they want to return cash to shareholders or manage the dilution from a loss-making sale.
For everyday investors, a larger buyback can be a positive signal. It suggests that management believes the stock is undervalued or that the company has confidence in its future cash flows. However, it's important to note that buybacks don't create value on their own—they simply redistribute it among fewer shares.
What It Means for Investors
ResMed's decision to sell at a loss and boost buybacks has several implications for shareholders. First, the company is acknowledging that its software diversification didn't pan out as expected. This is a reminder that even well-run companies can make acquisition mistakes. Second, the buyback provides some near-term support for the stock price, but the long-term story depends on how well ResMed can grow its core sleep apnea business.
The broader healthcare technology sector has seen mixed results from software acquisitions. While some companies have successfully integrated software into their offerings, others have found that the expected synergies didn't materialize. ResMed's experience mirrors that of other firms that have had to unwind acquisitions, such as Rio Tinto stepping back from a Malawi project or HSBC reviewing its Turkey retail banking operations.
Investors should watch for how ResMed uses the proceeds from the sale and whether the buyback is executed aggressively. The company's next earnings report will likely provide more details on its revised strategy and the expected impact on financials.
Looking Ahead
ResMed's focus now shifts to its core sleep and home care markets, which benefit from an aging population and growing awareness of sleep disorders. The company faces competition from other medical device makers, but its brand and distribution network give it a strong position. The sale of MatrixCare and HealthCare First may be a painful step, but it could ultimately help ResMed concentrate on what it does best.
For more on similar strategic shifts, see Fiserv exploring a STAR Network sale and Truist facing a murkier outlook under new leadership. These stories highlight how companies are constantly reassessing their portfolios to adapt to changing market conditions.
